Cart
sales@molnova.com
NSC 625987
CAS No. 141992-47-4
NSC 625987( NSC 625987 | NSC-625987 | NSC625987 | Cdk4 Inhibitor II )
Catalog No. M11755 CAS No. 141992-47-4
NSC 625987 is a potent, selective CDK4 inhibitor with IC50 of 0.2 uM, displays >500-fold selectivity over CDK2 (IC50 >100 uM for cdc2/cyclin A, cdk2/cyclin A and cdk2/cyclin E).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 50MG | 688 | Get Quote |
|
| 100MG | 1071 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameNSC 625987
-
NoteResearch use only, not for human use.
-
Brief DescriptionNSC 625987 is a potent, selective CDK4 inhibitor with IC50 of 0.2 uM, displays >500-fold selectivity over CDK2 (IC50 >100 uM for cdc2/cyclin A, cdk2/cyclin A and cdk2/cyclin E).
-
DescriptionNSC 625987 is a potent, selective CDK4 inhibitor with IC50 of 0.2 uM, displays >500-fold selectivity over CDK2 (IC50 >100 uM for cdc2/cyclin A, cdk2/cyclin A and cdk2/cyclin E).
-
In VitroNSC 625987 (10 nM, 50 nM, 100 nM) treatment attenuates the enhanced proliferation of vascular smooth muscle cells (VSMC) from spontaneously hypertensive rats (SHR) rats by about 35%.
-
In Vivo——
-
SynonymsNSC 625987 | NSC-625987 | NSC625987 | Cdk4 Inhibitor II
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number141992-47-4
-
Formula Weight271.33
-
Molecular FormulaC15H13NO2S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (368.55 mM)
-
SMILESS=C1C2=C(C=CC=C2)NC3=C(OC)C=CC(OC)=C13
-
Chemical Name1,4-Dimethoxy-9(10H)-acridinethione
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kubo A, et al. Clin Cancer Res. 1999 Dec;5(12):4279-86.
2. McInnes C, et al. Chem Biol. 2004 Apr;11(4):525-34.
3. Lang E, et al. Cell Physiol Biochem. 2015;37(3):1178-86.
molnova catalog
related products
-
PNU-112455A
PNU-112455A is an ATP-competitive CDK2/5 inhibitor with Ki of 2 uM and 2 uM for cdk2·GST-cyclin E and cdk5·GST-p25 respectively.
-
23-epi-26-Deoxyactei...
23-epi-26-Deoxyactein has anti-inflammatory activity, it inhibits nitric oxide production by reducing iNOS expression without affecting activity of the enzyme. It also has anti-cancer activity, it can inhibit growth of the MCF7 human breast cancer cells and induce cell cycle arrest at G1.
-
iCDK9
iCDK9 (i-CDK9) is a potent, highly selective CDK9 inhibitor (IC50<0.4 nM, CDK9-CycT1 kinase), exhibits >600-fold selectivity toward CDK1-CycB, CDK2-CycA, CDK4-CycD1, CDK7-CycH-MAT1 and CDK8-CycC.
